HCW Biologics Inc. (HCWB) Research
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Market snapshot
- Symbol
- HCWB
- Price
- $1.09
- Day change
- -0.91%
- Market cap
- $2.3M
- P/E ratio
- -1.40x
- 52-week range
- 0.25-7.35
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
Recent news
- Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss
HCW Biologics Inc. (NASDAQ:HCWB) stock fell during Tuesday's session. The company announced preliminary results from its Phase 1 trial for HCW9302, an IL-2-based treatment for alopecia areata.
- HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session
HCW Biologics Inc. surged 122.55% in after-hours trading after reporting first-quarter EPS that sharply exceeded analyst expectations.
Peer companies
Recent insider activity
- Wong Hing C — P-Purchase (113879 shares) on 2026-05-22
- Wong Hing C — P-Purchase (113879 shares) on 2026-05-22
- GARRETT SCOTT T — P-Purchase (177936 shares) on 2026-05-22
- GARRETT SCOTT T — P-Purchase (177936 shares) on 2026-05-22
- Byam Rebecca — P-Purchase (14235 shares) on 2026-05-22
Open HCW Biologics Inc. (HCWB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.